Vaxart (NASDAQ:VXRT – Get Free Report) was upgraded by research analysts at Wall Street Zen to a “buy” rating in a research report issued to clients and investors on Friday.
Vaxart Stock Performance
Vaxart stock opened at $0.67 on Friday. Vaxart has a 1 year low of $0.26 and a 1 year high of $0.84. The firm has a 50 day moving average price of $0.43 and a 200 day moving average price of $0.39. The company has a market cap of $161.08 million, a price-to-earnings ratio of -2.48 and a beta of 0.95.
Institutional Investors Weigh In On Vaxart
A number of institutional investors have recently added to or reduced their stakes in the company. Marshall Wace LLP purchased a new position in shares of Vaxart in the 2nd quarter worth about $794,000. Jones Financial Companies Lllp increased its position in Vaxart by 276,364.7% during the 1st quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock worth $196,000 after purchasing an additional 478,111 shares in the last quarter. Goldman Sachs Group Inc. acquired a new stake in Vaxart during the 1st quarter worth approximately $31,000. Creative Planning purchased a new position in Vaxart in the second quarter valued at approximately $33,000. Finally, Invesco Ltd. lifted its position in Vaxart by 93.1% during the first quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock valued at $60,000 after buying an additional 70,568 shares in the last quarter. Hedge funds and other institutional investors own 18.05% of the company’s stock.
Vaxart Company Profile
Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.
The company’s pipeline includes multiple vaccine candidates in various stages of development.
Featured Articles
- Five stocks we like better than Vaxart
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Do not delete, read immediately
- The $100 Trillion AI Story No One Is Telling You
- NEW LAW: Congress Approves Setup For Digital Dollar?
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.
